BMO vs IBN

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating marginal financial health, and the absence of an Altman Z-Score prevents a full solvency risk assessment. Despite solid profitability metrics like a 38.67% operating margin and strong revenue growth of 15.50%, earnings growth is inconsistent, with recent Q/Q declines and volatile quarterly surprises. The stock trades above its Graham defensive value of $127.87 at $137.69, yet below the analyst target of $127.91, while offering a solid 3.45% dividend yield with a sustainable 56.29% payout ratio. Technical trend sentiment is weak at 10/100, offsetting positive insider sentiment, resulting in a neutral overall stance.

The deterministic health profile is concerning, highlighted by a weak Piotroski F-Score of 2/9, indicating deteriorating operational trends. However, the valuation remains attractive with a PEG ratio of 0.52 and a current price ($27.54) sitting below the growth-based intrinsic value of $31.16. While revenue growth is explosive at 66.90%, the technical trend is currently bearish (0/100) and the 1-year price performance is negative. The stock presents a conflict between strong growth/valuation metrics and poor short-term financial health and price momentum.